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a b s t r a c t
Chemiluminescence, i.e. the emission of light from a chemical reaction, offers interesting opportunities
for developing point-of-care biosensors. However, commercially available systems are expensive, bulky,
and primarily addressed to laboratory usage. The goal of this paper is to present a novel work related to





serum. The new system has been especially developed for cost-sensitive applications using only low-
cost off-the-shelf components. The system was tested with blood serum. The output signal from spots
with speciﬁc proteins uptake was two orders of magnitude higher than that from control spots: it was
14±3mV/s from the detection spots, while it was only 260V/s and 242V/s from the control spots.




The interest in chemiluminescence assays increased very
apidly in the last decades. This detection technique enables chem-
cal and biochemical tests. It is very ﬂexible, and it achieves a
ensitivity of few pMol [1]. Hence, it has been used for detection of
xplosives [2], environmental control of soil and dusts [3], screen-
ng in food [4], bacteria identiﬁcation [5], biohazard applications
6], and for medical diagnostics [7,8]. The new frontier in diagno-
is is point-of-care testing. It is deﬁned as a testing at or near the
ite of patient care [9]. In this context, a distinctive advantage of
hemiluminescence with respect to ﬂuorescence and other optical
echniques is the absence of external light sources, which signif-
cantly simpliﬁes the implementation of detection systems [10].
owever, the available chemiluminescence detectors used in labo-
atory practice are still expensive and bulky. Therefore, they are not
uitable for hand-held point-of-care usage. A point-of-care usage
equires small and low-cost detectors. Size reduction is not a big
ssue, since single-chip approaches were already proposed in 1997
11]. Recently, anapplications-speciﬁc integrated circuit (ASIC)was
eveloped with an array of 128 detectors [6]. However, such ASIC
till have very signiﬁcant costs in terms of non-recurrent engi-
eering and production. Further cost reduction might come from
morphous silicon [12], but design-related costs will remain high
ue to a not so large and the extremely high level of parallelism in
he essay. On the other hand, Xin et al. reported quantitative deter-
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oi:10.1016/j.snb.2010.04.001minations of molecules by chemiluminescence directly in human
serum [13]. In particular, the aimwas the detection of cancermark-
ers. Despite aggressive treatments, itwasdemonstrated that cancer
patients have less than 5-year survival time if diagnosis is made at
an advanced stage. On the contrary, patients have higher chances
if cancer is diagnosed in an earlier stage [14]. However, the current
methods to detect cancer markers using chemiluminescence are
based on lab scanners, which are cumbersome, slow, and highly
expensive. These limitations affect the early detection of cancer
formation. Therefore, the development of low-cost devices is still
required to improve cancer diagnosis. Label-free techniques were
proposed as alternative to chemiluminescence, but they are still
underdevelopment and their sensitivity is still too low toefﬁciently
detect cancer markers in patient’s samples [15]. On the other hand,
the ELISA test based on chemiluminescence remains the best tech-
nique for early cancer detection. Therefore, optical point-of-care
devices are urgently required to replace ELISA test, more expensive
and complex, in order to perform diagnosis directly to the hospital.
Recently, Xu et al. [16] proposed a low-cost optical based on pho-
tomultipliers, but not suitable for point-of-care arrays. The aim of
the present paper is to illustrate a novel and successful design for
a point-of-care system, developed on board with low parallelism
(i.e. 2–8 detectors), very low-cost and off-the-shelf components.
The proposed solution is the best trade-off among low-volume,
cost-sensitive markets and limited parallelism essay.2. Materials and methods
The following section describes system architectures and
related materials for test and validation of the developed device
























































conversion operational ampliﬁer. The incident photons onto the
photodetector are converted intoaphotocurrent iph.Anoperational
ampliﬁer is required to develop the current-to-voltage converter
in order to acquire weak signals. The output voltage Vo is directly76 P. Grosso et al. / Sensors and
or chemiluminescentmeasurements. Twodifferent solutionswere
ested for signal ampliﬁcation and conditioning. A PC plug-in Lab-
IEW(National Instruments Inc., Austin, TX)DataAcquisitionboard
as used to acquire signals and a simple LabVIEW program was
eveloped to test the two different architectures.
.1. Choice of the detector
Regarding the choice of the detector, the goal is to detect
eeble light generated by a chemiluminescent reaction. Photoe-
ission rate can be extremely low, down to 4×105 photons/cm2 s
1.65×10−12 W/cm2) at emission wavelength of 480nm. Although
he choice of an optical detector is often complex, some key factors
hould be considered: quantum efﬁciency (QE), sensitivity, active
rea, minimum acceptable signal-to-noise ratio (SNR) and cost.
uantum efﬁciency is really important, since it is the ratio between
he number of electrons (or holes) generated as photocurrent and
he number of the incident photons. However, more often the SNR
s the most important feature used to choose the detector. In fact,
he noise of the detector has some components proportional to the
ignal and others independent from the signal. The independent
omponents consist of thermal noise (or Johnson noise) and dark
urrent noise. The Johnson noise (ij) is typical of solid-state detec-
ors, like avalanchephotodiodes (APDs) andphotodiodes (PDs), and







here k is the Boltzman constant, T is the absolute temperature,
is the frequency bandwidth and Rsh is the shunt resistance. The
ark current noise, or dark current shot noise, (isd) is expressed as
ollows:
sd = (2qIdB)1/2 (2)
here q is the electron charge and Id is the dark current. On the
ther hand, component depending on the signal is typically due to
tatistical ﬂuctuations:
SS = (2qISB)1/2 (3)
here IS is the photocurrent generated by the photoelectric effect.
hen, all these components contribute to SNR as:
NR = IS
(i2j + i2SD + i2SS)
1/2
= IS
(4KBT/Rsh + 2qIDB + 2qISB)1/2
(4)
Further noise source can come from non-speciﬁc molecular
inding, like interfering molecules that adhere non-speciﬁcally to
he sensing surface. This noise is not speciﬁcally related to the
etection, or to photodetectors. Indeed, it is related to proper-
ies of the sensing, and, in particular, to its nano-scale features
17]. Improvements to avoid non-speciﬁc molecular binding are
sually addressed by considering poly(ethylene glycol) (PEG), for
oating clean ELISA glass slides [18]. About photodetector-related
oise, a comparison was performed among different responses of
ommercially available systems, aiming to identify the key param-
ters of the detector in real systems. This comparison was done
sing a simple reaction of enhanced chemiluminescence (samples
ith 45L of luminol reagent, 45L of oxidizing reagent (HRP)
nd 10L of IGM–HRP conjugate). Three commonly-used systems
ere considered to check the performances of the photodetector.
he ﬁrstwas a Luminoskan (ThermoFisher Scientiﬁc Inc.,Waltham,
A)basedonphoto-multiplayerdetectors. The secondwasaKodak
mage station 4000 R – Chemidoc (CarestreamHealth Inc., formerly
odak Molecular Imaging Systems, Rochester, NY) based on a low
oise type of cooled CCD with high level of sensitivity in a wave-
ength region of 400–550nm. The third was a Scanner Storm 860Fig. 1. Comparison of tested photo-detector characteristics and the limits box
required to detect chemiluminescent signals.
Molecular Imager (Molecular Dynamics Inc., Sunnyvale, CA), which
is a CCD system with low quantum efﬁciency (20%) at 480nm.
The chosen photodetector to test was the commercial photodiode
OSD35-5T (OSI Optoelectronics, Hawthorne, CA), which presents
highquantumefﬁciency (64%) and sensitivity (0.25A/W) at awave-
length of 480nm. Fig. 1 summarizes different photo-detection
systems, showing that a quantum efﬁciency higher than 40% at
480nm, a sensitivity higher than 0.25A/W and a signal-to-noise
ratio higher than 20dB are required to detect a chemiluminescent
emission. Therefore, the photodiode OSD35-5T was chosen for our
application. It has a good signal-to-noise ratio, excellent quantum
efﬁciency (60%) and a good sensitivity (0.25A/W) at 480nm. More-
over, photodiodeshave also anexcellent linearity of output current,
as a function of the incident light. This kind of photodiodes do not
require high voltages and they are suitable for dense arrays. Fur-
thermore, they are cheaper compared with avalanche photodiodes
and other high-sensitivity detectors.
2.2. Signal conditioning architectures
Two circuits were designed and compared. The ﬁrst light
detection circuit (Fig. 2) presents a high-speed current-to-voltageFig. 2. Circuit architecture proposed with a photodiode and a trans-impedance
ampliﬁer.
























hig. 3. Circuit architecture proposedwith aphotodiode andanoperational ampliﬁer
ntegrator.
elated to the generated current:
o = iphR (5)
The second detection circuit presents an integrator circuit
Fig. 3). In this second architecture, the photocurrent generated
y incident photons charges a capacitor. The amount of charge is
imited by the diffusion well capacity. The average photocurrent is
btained from the integration of the output voltage Vo across the
apacitance C over the time. A low dielectric absorption capacitor
s used to suppress reset errors.
.3. System on board
Two printed circuit boards (PCB) are designed and fabricated
o implement the two aforementioned conﬁgurations. The boards
resent two levels of copper (top and bottom sides of the board).
omponentsplacement is chosen inorder tominimize theoccupied
rea and to support critical contacts. Fig. 4 shows the current-
o-voltage conversion board and the related space available for
ousing a typical ELISA test glass slide. A DC voltage of 12V is the
nput voltage. The operational ampliﬁer OPA 111 works with dual
upply power of ±5V. Component TEN 1221 (Traco Power) is used
o generate the three reference voltages of +5V, −5V and ground.
hotodiodes are connected between the two inputs of the trans-
mpedance ampliﬁers. They are polarized with 0V and, thus, they
ig. 4. Current-to-voltage conversion board. The image also schematically shows
ousing of typical glass slide used in ELISA tests.Fig. 5. Boardwith the integration circuit. The image also schematically shows hous-
ing of typical glass slide used in ELISA tests.
have the highest possible sensitivity. Output current is very low,
about 200pA. For this reason, an accurate resistance of 10M was
selected to obtain a measurable voltage value. The potentiometer
trimmers (10k to 1M) were inserted in order to suppress offset
of the operational ampliﬁer. Instead, Fig. 5 shows the board with
the integrator circuit and enough available room for housing a typ-
ical glass slide used in ELISA tests. In this second architecture, the
output current is integrated to obtain the charge in the capacitors.
At the end of the integration time Tint, the capacitors are reset by
means of transistor-driven reed-relays. A capacitor of exactly 1nF
is used because the output current of the sensors is very low.
The two boards, implementing two different detection circuits,
were ﬁnally packaged in a metal box, in order to avoid electrical
noise and to investigate possible integration in point-of-care sys-
tems. The box was also used to create a dark chamber to ﬁlter out
the external light.
2.4. Chemiluminescence tests
Luminol molecule and hydrogen peroxide as oxidizing agent
were chosen to test and validate the two developed circuits and the
optical detector. These compounds can react with the horseradish
peroxide (HRP), a very well know enzymes used in chemilu-
minescence assays, and produce the excited compound 3-APA
(3-aminophthalate). The decay form a high to a lower energy level
is responsible for the emission of light [19]. A microscope slide was
spotted with 20L drops of a mixture of 45L of luminol reagent,
45L of oxidizing reagent and 10L of HRP covalently linked to an
immunoglobulin M (IgM–HRP conjugate). After spotting, the slide
was immediately positioned into themeasuring chamber exactly in
the positions showed in Figs. 4 and 5. Chemiluminescent signalwas
measured by means of three different systems: (i) the developed
system based on current-to-voltage conversion, (ii) the developed
system based on the integration circuit, (iii) a commercial available
luminometer speciﬁcally developed for chemiluminescent applica-
tions (Luminoskan).
2.5. Validation on cancer marker detectionThe sandwich immunoassay is prepared with the protocol
reported by Collins et al. [20]. Primary antibody (the “capture”
antibody) was immobilized onto a well plate. Antigen was then
added and allowed to form a complex with the primary antibody.
Unbound products were then removed by washing. A labelled sec-













































The different signals measured during tests to calculate the signal-to-noise ratios.
signal-to-noise ratio equal to 20was obtained using the integration
circuit board. All these results demonstrate that the board based
on integrator circuit is better than the board based on current-to-
voltage conversion. Hence, the board based on integrator circuit is
chosen for the immunoassay tests.
Fig. 7. Time trend of the chemiluminescent signal acquired using the current-to-
voltage conversion.ig. 6. Signals acquiredwith the two different detection circuits in comparisonwith
hose acquired using a commercially available luminometer.
nd antibody (the probe) was allowed to bind the antigen (from
ere the expression “sandwich”). This technique has two main
dvantages: the target antigen does not need to be puriﬁed prior to
se, and the assay has very high speciﬁcity. Reagents of the reaction
ere Slides Superfrost Plus Menzel (used for electrostatic bind-
ng of the primary antibodies), Anti-Human IgM (Sigma I0140),
nti-Human IgM (-chain) peroxidase conjugate (Sigma A0420),
hosphate Buffer Saline pH 7.2 (buffer is used to maintain a con-
tant pH in order to prevent proteins denaturation), PBS-Tween
.05% –wash buffer (detergent), PBS–BSA 1% – block buffer (Bovine
erum Albumin is used to ﬁll slide spaces not previously covered
y the ﬁrst antibody), Human Serum Samples, Western Lightning
hemiluminescence Reagent Plus (NEL105001EA PerkinElmer).
. Results and discussion
.1. Test of the two solutions
Fig. 6 depicts the behaviors of chemiluminescent signals vs. time
or the three considered systems. All the curves show the typi-
al exponential decay of chemiluminescent emission. The three
ifferent systems are compared with respect to different curve
arameters. The estimation of chemiluminescence decay constants
as ﬁrstly considered. A decay constant value equal to −0.055
as measured using the integration circuit board. This value is
uite close to −0.049, the one obtained using the luminometer. On
he other hand, a value equal to −0.079 was measured using the
oltage-to-current board. This last value is not very close to of the
revious one related to the luminometer. It means that sensitivity,
etection limit, and dynamic range of the device are better for the
ntegrator circuit, since the results are closer to those obtainedwith
ommercially available luminometers.
The signal-to-dark ratio is also estimated and compared. Val-
es are calculated from the average of 10 different measurements
t a sampling rate of 10 samples/s. As shown in Table 1, measure-
ents for the dark-ﬁeld results equal to 4.6±1.3pA in the case of
oltage-to-current conversion, while the maximum luminescent
ignal is 320±1.3pA. In this case, the signal-to-dark ratio is about
0. Instead, the dark-ﬁeld output in the case of the integration cir-
uit is equal to 2.64±0.92pA with a maximum luminescent signal
qual to 404±0.92pA. In this case, the signal-to-dark ratio is about
53. Therefore, the board based on integration circuit presents a
ignal-to-dark ratio twice higher than the value obtained with the
urrent-to-voltage conversion.
able 1




Dark current signal (pA) 4.6±1.3 2.64±0.92




Maximum noise signal 0.4±0.1 20±1
Maximum detected signal 3.2±0.1 404±1
The signal-to-noise ratio is determined by characterizing the
noise affecting maximum chemiluminescent signal. The output
voltagewas sampledwith a sapling timeof 100ms in the case of the
board based on current-to-voltage conversion. The average of the
samples is considered as the maximum chemiluminescent signal,
while the standard deviation is assumed as the noise affectingmea-
surements. By following thismethod, themaximumdetected signal
was acquired in 3.2mV with a noise of 0.4mV, as shown in Table 2.
Fig. 7 reports an example of the current acquired during thesemea-
surements. Therefore, the signal-to-noise-ratio is about 8 for the
current-to-voltage conversion board. In the case of integration cir-
cuit, the capacitance charge is linear over 5 s. The photocurrent can





Then, the output voltage is sampled with a sampling time of
100ms, in order to determine the signal-to-noise ratio; the slope
between two subsequent samples is calculated; ﬁnally the mean
value of the slopes was considered as the maximum chemilumi-
nescent signal, while the standard deviation was considered as the
noise. In this way, the maximum detected signal was 404pA with
a noise equal to 20pA, as summarized in Table 2. Fig. 8 reports an
example of the signal acquired during thesemeasurements. Thus, aFig. 8. Time trend of the chemiluminescent signal acquired using the integration
circuit.


















































[ig. 9. Results obtained with an immunoassay on human serum for the detection
f cancer markers.
.2. Validation on cancer-assay
The integrator boardwas used to detect the chemiluminescence
ignal in an immunoassay sandwich in order to validate the system.
he system is tested in human serum with a functionalization of
ntibodies for the inhibition of human immune complexes.
Twodifferent reactions (immuneassays)wereperformedon the
ame glass slide. In the ﬁrst, a complete immune-complex sand-
ich was formed (this spot is able to glow chemiluminescence);
n the second (the negative control spot) the absence of probe
ntigens assure no uptake of the target antigens, and, thus, the
bsence of chemiluminescence. Only non-speciﬁc molecular bind-
ng is expected from this spot. As further control, the areas of the
hird and fourth photodiodes are not covered with the solution,
n order to only measure dark currents. Just prepared slides were
mmediately inserted into the measuring chamber, being care-
ul with the alignment between the photodiodes array and the
unctionalized spots in the slide. Then, the different photodiodes
esponses were acquired and compared. The output voltage of the
ystem was sampled with an interval of 100ms, as was done in the
revious test. Fig. 9 shows the experimental results. The photosig-
al returned amaximumcurrent value of 14±1.2pA (sites top left)
n the case of measurements from the spot where immune com-
lexeswere formed. On the contrary,when the immune complexes
ere not formed (site top right), the obtained value (290 fA) was
lose to of the one obtained in the dark ﬁeld (242 fA as average from
ottom sites). The signal from the ﬁrst site also decreases exponen-
ially over the time, approaching the dark-ﬁeld signal-value within
min, accordingly with chemiluminescence decay. These currents
ignalswere estimated by the acquired output voltages. These volt-
ges were measured equal to 14±1.2mV/s on spot containing the
atchingmolecules (the full sandwichof probes and targets), equal
o 290V/s on spot containing the molecular control (spot with-
ut primary antibodies), and equal to 242V/s on spots without
hemistry (used to measure the dark currents).
The maximum chemiluminescent signal obtained in the
mmunoassay with human serum (Fig. 9) is smaller than those
cquired in the experiments with the luminol alone (Fig. 8). This is
ue to the number of enzymes immobilized onto the slide surface,
hich affects the total emission intensity.
. ConclusionIn this paper the feasibility of a devices based on low-cost off-
he-shelf components is investigated for parallel ELISA assay. Data
rom two different circuit architectures (current-to-voltage con-
ersion and current integration) are compared, in order to identify
he best one. The two proposed architectures are developed on
[
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PCB and packaged with a portable camerafor point-of-care appli-
cations. The best results were obtained with the architecture based
on current integration. This circuit is validated with immunosen-
sor assay. A signal equal to 14±1.2pA is measured, corresponding
to chemiluminescent from spots where the immune complexes
were formed. A signal of 290 fA is instead measured from those
spots where the immune complexes were not formed. Signals
from spots with non-speciﬁc molecular binding were very close
to those obtained in dark-ﬁeld conditions. The developed system
also detected the exponential decay of chemiluminescent emis-
sions. Hence, the present study demonstrated the feasibility of the
proposed system for the development of point-of-care devices in
immune assay. This work paves the way to portable, fast, sensi-
tive, and very low-cost point-of-care devices for early detection of
cancer markers using ELISA tests. Even in prototype form, the total
cost of the system, was 52 times lower than commercially avail-
able luminometers, and 75 times lower than the high-sensitivity
scanners.
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